Something is shifting in mental health science. Treatments that seemed futuristic a decade ago are now being refined, compared, and brought into the clinic. New findings from the past few weeks illustrate what that progress looks like in practice — and why it matters for the millions of people who haven’t yet found relief.
The Best Head-to-Head Ketamine Data Yet
For people with treatment-resistant depression (TRD) — defined as persistent symptoms despite trying at least two antidepressants — the landscape of options has quietly transformed. Two forms of ketamine therapy are now part of the clinical toolkit: intravenous (IV) ketamine and intranasal esketamine (sold as Spravato, and FDA-approved for TRD since 2019). But until recently, clinicians had little direct evidence comparing the two.
That changed with a new study from McLean Hospital (part of Mass General Brigham), published in the Journal of Clinical Psychiatry. Researchers analyzed 153 adults with severe TRD — one of the largest naturalistic comparisons of these two treatments to date. Both reduced depression significantly. But IV ketamine showed a 49.22% reduction in depression scores by the final dose, compared with 39.55% for the esketamine nasal spray. IV ketamine also worked faster — patients often showed improvement after their very first treatment session, while esketamine’s improvements became significant after the second.
“Both IN esketamine and IV ketamine are important tools in the evolving neuropsychiatric toolkit,” said study first author Dr. Robert Meisner, medical director of the Ketamine Service at McLean. The researchers are careful to note that insurance coverage, ease of access, and the patient’s specific clinical profile should all factor into the choice — IV ketamine remains off-label, while esketamine is FDA-approved. And both treatments require careful oversight to guard against misuse.
Separately, the American Psychiatric Association’s June 2026 American Journal of Psychiatry published new research on the mechanisms behind ketamine’s anti-suicidal effects — specifically, the role of opioid receptors in sustaining its benefits. Understanding why ketamine works may help researchers develop next-generation treatments that extend its gains.
For the roughly 30% of people with major depression who don’t respond to standard antidepressants, this growing body of evidence is genuinely good news. The tools are getting sharper, and the clinical community is learning how to use them more precisely.
Ozempic’s Unexpected Mental Health Benefits
Perhaps the most striking finding of the past month comes from a very different direction. GLP-1 receptor agonists — the class of medications that includes semaglutide (Ozempic, Wegovy) and liraglutide — are best known for treating diabetes and supporting weight loss. But a landmark study published in Lancet Psychiatry this spring suggests they may also meaningfully protect mental health.
Researchers from the University of Eastern Finland used national Swedish health registers to track 95,490 people with diagnosed depression or anxiety who were taking antidiabetic medications. Using a within-individual design — comparing each person’s own periods on and off GLP-1 medications — they found that semaglutide was associated with a 44% lower risk of worsening depression, a 38% lower risk of worsening anxiety, and a 47% lower risk of worsening substance use disorder. GLP-1 drugs as a class were also associated with a 44% reduced risk of self-harm.
These are striking numbers. The within-person design is one of the study’s strengths: because it compares each individual to themselves at different times, it controls for many of the confounding factors that complicate other observational studies. The authors note this appears to be the first such study with this design showing that GLP-1 users were less likely to experience worsening mental illness.
Important caution: these are still observational findings, not randomized controlled trials. Some pharmacovigilance data have flagged possible adverse signals with semaglutide in certain populations. Researchers agree that RCTs are needed before this reshapes mental health prescribing. But the signal is real, it’s large, and it points toward biology that researchers are now actively exploring — GLP-1 receptors are present in key brain regions involved in mood, reward, and stress response.
Suicide Prevention in the Everyday Doctor’s Office
Most people who die by suicide visited a healthcare provider in the month beforehand — but for most of that time, primary care has not been a site of systematic suicide prevention. A landmark NIMH-funded trial is changing that picture.
The study, part of the National Zero Suicide Model initiative at Kaiser Permanente Washington, analyzed 1.5 million+ primary care visits at 22 clinics. When clinics added suicide screening, risk assessment, and collaborative safety planning to routine visits, suicide attempts in the 90 days after a primary care appointment dropped by 25%. These are not specialty psychiatric settings — these are ordinary clinics where people go for checkups and referrals.
Separately, NIH-funded researchers developed new EHR-based suicide risk prediction models using data from the Indian Health Service, expanding this kind of predictive tool to Indigenous populations — a community with historically disproportionate suicide rates and historically underserved by mainstream research.
The lesson is clear: suicide prevention doesn’t have to wait for a referral to a specialist. It can happen in the office where you already go. Scaling that insight is the work ahead.
The World’s Largest Prize for Mental Health Science
One more development worth celebrating: on May 14, 2026, Wellcome Trust and Nature launched the Wellcome Prize for Mental Health Science — the world’s largest prize dedicated to mental health research. The winning team will receive $1 million, with three finalists each awarded $250,000. The prize targets new interventions for anxiety, depression, and psychosis, and is open to research teams anywhere in the world. Applications are open through September 18, 2026.
The ambition behind the prize is larger than the money: to shift the public narrative on mental health from crisis to opportunity, and to catalyze funder investment in a field that has long been underfunded relative to its burden. As Nature’s editorial accompanying the launch noted, mental health interventions have historically been shaped more by social control than therapeutic intent. Prizes change what gets celebrated — and what gets resourced.
Taken together, these advances tell a story of a field that is genuinely making progress. Treatments are getting better. The clinical evidence base is getting sharper. And the systems that support research are, slowly, scaling up. For everyone living with depression, anxiety, serious mental illness, or loss — that progress is not abstract. It is the next generation of help.
This post covers field developments from the week of June 22–29, 2026. Sources include the Journal of Clinical Psychiatry, Lancet Psychiatry, the APA, NIMH, and Wellcome Trust. This post does not constitute medical advice. Please consult a qualified clinician for treatment decisions.